Tenaya Therapeutics (TNYA)
NASDAQ:TNYA
Want to see TNYA full AI Analyst Report?
Top Page
Tenaya Therapeutics
(NASDAQ:TNYA)
Select Model
Select Model
Rating:52Neutral
Price Target:
$0.78
▼(-41.35% Downside)
Action:Reiterated
Date:05/09/26
The score is held back primarily by weak financial performance (minimal revenue, large losses, and sustained cash burn). Offsetting factors include constructive near-term technical strength (though overbought signals raise pullback risk) and a positive strategic collaboration that provides potential non-dilutive upside and reduced downstream cost exposure.
Positive Factors
Strategic collaboration
The Alnylam collaboration transfers downstream development, manufacturing, regulatory and commercialization costs to a large partner while providing up to $10M upfront and material milestone upside. This materially lowers Tenaya's near-term funding needs, validates its platform, and creates non-dilutive, milestone-linked upside that strengthens long-term capital efficiency and partner-driven de‑risking of programs.
Negative Factors
High cash burn
Sustained negative operating and free cash flow near -$64M annually creates ongoing financing needs. Even with some improvement versus prior years, persistent burn means Tenaya remains reliant on partner payments, milestone receipts, or capital markets to fund R&D, elevating dilution or program cut risks if funding or milestones are delayed.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic collaboration
The Alnylam collaboration transfers downstream development, manufacturing, regulatory and commercialization costs to a large partner while providing up to $10M upfront and material milestone upside. This materially lowers Tenaya's near-term funding needs, validates its platform, and creates non-dilutive, milestone-linked upside that strengthens long-term capital efficiency and partner-driven de‑risking of programs.
Read all positive factors
Tenaya Therapeutics (TNYA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$169.69M
Dividend YieldN/A
Average Volume (3M)4.00M
Price to Earnings (P/E)―
Beta (1Y)2.68
Revenue GrowthN/A
EPS Growth59.42%
CountryUS
Employees97
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.47
Shares Outstanding216,998,870
10 Day Avg. Volume2,873,734
30 Day Avg. Volume4,003,933
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.88
Price to Sales (P/S)0.00
P/FCF Ratio-1.58
Enterprise Value/Market Cap0.34
Enterprise Value/Revenue257.47
Enterprise Value/Gross Profit177.70
Enterprise Value/Ebitda-0.75
Forecast
1Y Price Target
$10.33Price Target Upside676.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$8.51M
Tenaya Therapeutics Business Overview & Revenue Model
Company Description
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The com...
How the Company Makes Money
Tenaya Therapeutics is a clinical-stage biotechnology company; specific, consistent product-based commercial revenue is not publicly available in the provided context, and the company has historically operated primarily by funding R&D through exte...
Tenaya Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
56
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 225.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 326.00K | -8.44M | -8.47M | -8.69M | -8.71M | -4.03M |
| EBITDA | -77.52M | -84.89M | -102.66M | -115.40M | -114.95M | -68.70M |
| Net Income | -83.00M | -90.60M | -111.13M | -124.08M | -123.67M | -72.72M |
Balance Sheet | ||||||
| Total Assets | 135.07M | 146.92M | 119.94M | 170.51M | 278.94M | 316.65M |
| Cash, Cash Equivalents and Short-Term Investments | 80.89M | 100.55M | 61.45M | 104.64M | 186.53M | 251.30M |
| Total Debt | 10.12M | 10.83M | 13.61M | 12.42M | 15.10M | 15.70M |
| Total Liabilities | 28.88M | 23.66M | 27.09M | 31.09M | 35.57M | 38.12M |
| Stockholders Equity | 106.19M | 123.27M | 92.85M | 139.42M | 243.38M | 278.53M |
Cash Flow | ||||||
| Free Cash Flow | -64.63M | -68.88M | -91.53M | -103.31M | -125.05M | -85.93M |
| Operating Cash Flow | -64.39M | -68.26M | -90.50M | -102.07M | -104.42M | -60.81M |
| Investing Cash Flow | 33.77M | 56.08M | 1.13M | 48.72M | 83.65M | -238.56M |
| Financing Cash Flow | 57.73M | 108.41M | 47.75M | 4.05M | 77.77M | 208.97M |
Tenaya Therapeutics Technical Analysis
Neutral
1.33
Price Trends
0.76
Positive
0.75
Positive
1.03
Negative
Market Momentum
0.01
Positive
48.57
Neutral
12.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNYA, the sentiment is Neutral. The current price of 1.33 is above the 20-day moving average (MA) of 0.83, above the 50-day MA of 0.76, and above the 200-day MA of 1.03, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 48.57 is Neutral, neither overbought nor oversold. The STOCH value of 12.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TNYA.
Tenaya Therapeutics Risk Analysis
Tenaya Therapeutics disclosed 67 risk factors in its most recent earnings report. Tenaya Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tenaya Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $312.90M | -3.71 | 41.40% | ― | ― | ― | |
55 Neutral | $582.50M | -8.62 | -60.42% | ― | ― | 26.28% | |
52 Neutral | $169.69M | -1.37 | -80.56% | ― | ― | 59.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $565.89M | -5.75 | -32.33% | ― | ― | 38.99% | |
47 Neutral | $231.41M | -2.06 | -55.97% | ― | -45.50% | -35.63% | |
41 Neutral | $183.74M | -9.09 | 21.05% | ― | ― | 43.38% |
* Healthcare Sector Average
TNYA
Tenaya Therapeutics
0.79
0.35
79.59%
GALT
Galectin Therapeutics
2.70
1.41
109.30%
ABEO
Abeona Therapeutics
5.69
-0.30
-5.01%
VYGR
Voyager Therapeutics
3.93
1.20
43.96%
TECX
Tectonic Therapeutic
30.43
8.88
41.21%
CADL
Candel Therapeutics
8.05
2.11
35.52%
Tenaya Therapeutics Corporate Events
Business Operations and Strategy
Tenaya Therapeutics Announces Major Cardiovascular Gene Target Collaboration
Positive
Mar 5, 2026
On March 4, 2026, Tenaya Therapeutics entered into a collaboration agreement with Alnylam Pharmaceuticals to jointly discover and validate up to 15 novel gene targets for potential cardiovascular disease treatments over an initial 24‑month r...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.